---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-337069"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2026-08-06T14:08:06+00:00"
generated_at: "2026-08-06T14:09:06.957394+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Therapeutics Q2 net loss narrows to $16.6M; cash $190M, runway into 2H 2028

## Summary
- Net loss of $16.6M for Q2 2026, compared to $52.6M in Q2 2025; R&D expenses fell to $12.9M from $48.8M.
- Cash, equivalents and short-term investments $190.0M at June 30, 2026, up from $145.7M at Dec 31, 2025.
- Completed $87.5M private placement equity financing in May 2026 with existing and new investors.
- Phase 1 trials for HWK-007 and HWK-016 continue enrolling; initial results expected in 1H 2027.
- Entered option agreement with Hangzhou DAC for CPT113 linker-payload and collaboration with Biocytogen for bispecific ADCs.

## SEC filing metadata
- accession: 0001193125-26-337069
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2026-08-06T14:08:06+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/0001193125-26-337069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-337069
- JSON: https://secwatch.observer/filing/0001193125-26-337069.json
- Plain text: https://secwatch.observer/filing/0001193125-26-337069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.